BioVie (BIVI)
(Real Time Quote from BATS)
$0.50 USD
+0.02 (3.14%)
Updated Apr 29, 2024 11:56 AM ET
3-Hold of 5 3
D Value B Growth B Momentum C VGM
Income Statements
Fiscal Year end for BioVie Inc falls in the month of June .
All items in Millions except EPS data.
6/30/23 | 6/30/22 | 6/30/21 | 6/30/20 | 6/30/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 45 | 27 | 138 | 3 | 3 |
Income After Depreciation & Amortization | -45 | -27 | -138 | -3 | -3 |
Non-Operating Income | -1 | 3 | 8 | -9 | 0 |
Interest Expense | 4 | 2 | 1 | 5 | 0 |
Pretax Income | -50 | -26 | -130 | -17 | -2 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -50 | -26 | -130 | -17 | -2 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -50 | -26 | -130 | -17 | -2 |
Depreciation Footnote | 6/30/23 | 6/30/22 | 6/30/21 | 6/30/20 | 6/30/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -45 | -27 | -138 | -2 | -2 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -45 | -27 | -138 | -3 | -3 |
Earnings Per Share Data | 6/30/23 | 6/30/22 | 6/30/21 | 6/30/20 | 6/30/19 |
---|---|---|---|---|---|
Average Shares | 32.48 | 24.66 | 12.40 | 4.93 | NA |
Diluted EPS Before Non-Recurring Items | -1.55 | -1.06 | -14.82 | -6.85 | NA |
Diluted Net EPS (GAAP) | -1.55 | -1.06 | -14.82 | -6.85 | NA |
Fiscal Year end for BioVie Inc falls in the month of June .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 8.78 | 10.88 | 10.98 | 13.78 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -8.78 | -10.88 | -10.98 | -13.78 |
Non-Operating Income | NA | 1.20 | 1.17 | 2.97 | -0.18 |
Interest Expense | NA | 0.82 | 1.00 | 1.11 | 1.08 |
Pretax Income | NA | -8.40 | -10.71 | -9.11 | -15.04 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -8.40 | -10.71 | -9.11 | -15.04 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -8.40 | -10.71 | -9.11 | -15.04 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 38.17 | 36.74 | 32.48 | 35.33 |
Diluted EPS Before Non-Recurring Items | NA | -0.22 | -0.29 | -0.23 | -0.43 |
Diluted Net EPS (GAAP) | NA | -0.22 | -0.29 | -0.24 | -0.43 |